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Abstract
Surgery is the most effective therapy for cancer in the United States, but disease still recurs in more than 40% of
patients within 5 years after resection. Chemotherapy is given postoperatively to prevent relapses; however, this
approach has had marginal success. After surgery, recurrent tumors depend on rapid neovascular proliferation to
deliver nutrients and oxygen. Phosphatidylserine (PS) is exposed on the vascular endothelial cells in the tumor micro-
environment but is notably absent on blood vessels in normal tissues. Thus, PS is an attractive target for cancer
therapy after surgery. Syngeneic mice bearing TC1 lung cancer tumors were treated with mch1N11 (a novel mouse
chimeric monoclonal antibody that targets PS), cisplatin (cis), or combination after surgery. Tumor relapses and
disease progression were decreased 90% by combination therapy compared with a 50% response rate for cis alone
(P = .02). Mice receiving postoperative mch1N11 had no wound-related complications or added systemic toxicity in
comparison to control animals. Mechanistic studies demonstrated that the effects of mch1N11 were associated with
a dense infiltration of inflammatory cells, particularly granulocytes. This strategy was independent of the adaptive
immune system. Together, these data suggest that vascular-targeted strategies directed against exposed PS may
be a powerful adjunct to postoperative chemotherapy in preventing relapses after cancer surgery.
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Introduction
Surgery is the best option for cure in most solid tumors in the United
States; however, this treatment has a 40% to 60% recurrence rate de-
pending on the type of cancer [1]. For example, in non–small cell lung
cancer (NSCLC), more than 50% of patients with resectable stage I to
IIIA cancer will have recurrence after surgery. Many of these re-
currences occur from residual tumor deposits in the resection margins,
which rapidly proliferate after removal of the primary tumor. As a con-
sequence, cisplatin (cis) chemotherapy is typically administered as an
adjuvant after surgery to prevent relapses [2]. However, this approach
improves the 5-year survival rate by a marginal 4% [3].
Most clinically effective adjuvant anticancer therapies are based
on their ability to directly kill dividing tumor cells as they begin to
Abbreviations: cis, cisplatin; PS, phosphatidylserine; VEGF, vascular endothelial
growth factor
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proliferate. However, therapies that target other cells within the prolif-
erating tumor deposits in the local wound after surgery are now being
developed. For example, compared with the normal tissue beds, the
vasculature in tumors exhibits an increased rate of proliferation, struc-
tural differences, and expression of unique genes and gene products
[4,5]. The tumor endothelium has been successfully targeted by drugs
that inhibit angiogenesis. The efficacy of an anti–vascular endothelial
growth factor (VEGF) antibody to inhibit tumor angiogenesis has
been shown in colon and lung cancer [6–8]. Another category of drugs
classified as vascular-disrupting agents have also been developed that
can specifically affect established tumor vessels [9,10]. The agent used
in this study, a phosphatidylserine (PS)-targeting antibody, also binds
to and destroys the tumor vasculature.
PS is the most abundant anionic phospholipid of the plasma mem-
brane and is tightly segregated to the inner leaflet of the plasma
membrane in most mammalian cells. However, PS expression is sig-
nificantly increased on tumor-associated blood vessels and is external-
ized in 15% to 40% of tumor vessel endothelia [10]. PS is notably
absent from the vasculature of normal tissues [11,12]. The tumor
microenvironment has hypoxic and acidic conditions that are rich in
cytokines, leukocytes, thrombin, metabolites, and reducing/oxidizing
factors that may explain the high expression of PS on vessels penetrating
carcinomas [10–12]. These stresses elicit the production of reactive
oxygen species, which may oxidize membrane phospholipids and
generate calcium fluxes that inhibit the ATP-dependent transporter
aminophospholipid translocase and/or activate PS-exporting enzymes
[13]. In this study, we investigate the use of PS as a target on the
endothelial cells of new vessels that develop in recurrent tumors as they
begin to proliferate after surgery.
Mch1N11 is a novel mouse chimeric immunoglobulin G 2A anti-
body that binds to and stabilizes complexes of PS and the PS-binding
plasma protein, β2-glycoprotein I. The antibody only binds to cell sur-
faces on which PS is exposed. One of the functions of exposed PS is
to silence unwanted inflammatory responses and immune responses
against normal cells undergoing apoptosis at the end of their natural
life span. However, in tumors, exposed PS has anti-inflammatory and
immunosuppressive actions that dampen the host’s ability to control
tumor growth. Treatment with PS-targeting antibodies thus evokes
an antitumor inflammatory response. Previous studies have shown that
PS-targeting antibodies are effective against pancreatic, breast, and
lung cancers [13–15]. Furthermore, it has been shown in murine
models that PS-targeting antibodies are most effective when combined
with radiation and/or chemotherapy (i.e., docetaxel, gemcitabine) [13–
15]. The PS-targeting antibody, bavituximab, has completed phase 1
studies [10,16] and is currently in randomized phase 2 trials in pa-
tients with lung and pancreatic cancers. To our knowledge, the present
study is the first to use a PS-targeting antibody in an adjuvant setting
when there is a rapidly changing vascular bed around tumor deposits
after surgery.
In this project, we examined whether a PS-targeting antibody can
be combined with cis after surgery to improve outcomes. We pos-
tulated that this combination of cis/mch1N11 would be uniquely
potent after surgery owing to several mechanistic advantages. First,
cis is the standard of care for lung cancer after surgery and is known
to enhance PS exposure in the tumor microenvironment [17,18]. Sec-
ond, mch1N11 and cis are complementary after surgery when tumor
deposits in the local wound begin to proliferate. Mch1N11 attacks the
hypoxic core of a new rapidly expanding tumor, whereas cis attacks the
rapidly dividing tumor cells of the oxygenated tumor periphery [15].
Third, surgery is known to create a unique environment for new blood
vessel development owing to changes in angiogenic factors (e.g.,
VEGF) [4]. Thus, we postulated that this postoperative environment
would be particularly susceptible to vascular-targeting strategies such as
mch1N11. Finally, a major concern of using other antivascular strate-
gies (such as commercially available bevacizumab) is wound healing
complications. We did not find this toxicity with our novel agent. In
summary, our data demonstrate that, when combined with cis, the
PS-targeting antibody enhances tumor killing, prevents relapses, and
slows the progression of tumor recurrences after surgery.
Materials and Methods
Animals
Female C57BL/6 (B6, Thy1.2) mice were purchased from Charles
River Laboratories (Malvern, PA). All mice were maintained in
pathogen-free conditions and used for experiments at ages 8 weeks
or older. The Animal Use Committees of the Children’s Hospital of
Philadelphia, The Wistar Institute, and the University of Pennsylvania
approved all protocols in compliance with the Guide for the Care and
Use of Laboratory Animals.
Cell Lines
TC1 cells were derived from mouse lung epithelial cells of a
C57BL/6 mouse, immortalized with human papillomavirus type
16 E6 and E7, and transformed with the c-Ha-ras oncogene [19].
The TC1 cell line was maintained in RPMI medium supplemented
with 10% heat-inactivated fetal bovine serum, 1% glutamine, and
1% penicillin and streptomycin. Cells were cultured at 37°C in a
humidified incubator containing 5% CO2.
Chemotherapy
Cis was purchased from APP Pharmaceuticals, LLC (Schaumburg,
IL). Cis was administered intraperitoneally (i.p.) once weekly to mice
at 6 mg/kg for C57BL/6 mice. Cis was suspended in 200 μl of normal
saline for i.p. injections.
Antibodies
The mouse chimeric antibody, mch1N11, is a mouse immuno-
globulin G 2A version of a fully human PS-targeting antibody
(PGN635) directed against PS–β2-glycoprotein I complexes. The
specificity of PGN635 is similar to that of the chimeric antibody,
bavituximab. PGN635 was generated by Peregrine Pharmaceuticals
Inc (Tustin, CA) in conjunction with Affitech AG (Oslo, Norway).
C44 is an isotype-matched control antibody for mch1N11. Both C44
and mch1N11 were purified as previously described [20].
Animal Flank Tumor Models
C57BL/6 mice were inoculated subcutaneously on the right flank
with 1.2 × 106 TC1 cells. When the tumors reached approximately
250 mm3, mice were randomized and grouped into four cohorts: 1)
C44 antibody only, 2) cis + C44 antibody, 3) mch1N11 antibody only,
and 4) cis + mch1N11 antibody. A weekly treatment cycle was set up
on day fourteen when the tumors approached 300 mm3: mice from
groups 1 and 3 were treated with 100 μg of antibody, whereas mice
from groups 2 and 4 were treated with 100 μg of antibody and 3 or
6 mg/kg of cis. Antibodies were injected biweekly, whereas cis was
injected weekly. A total of five antibody and three cis injections were
completed during the course of the experiment. Tumor dimensions
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were measured at the time of injection with calipers and tumor size was
determined by the equation: π/6 × length × width × width. All experi-
ments had at least five mice per group and were repeated at least once.
Surgery
Surgery was performed on mice bearing flank tumors using an
established partial resection model [21]. Partial resection was per-
formed on C57BL/6 mice inoculated subcutaneously with 1.2 ×
106 TC1 cells. Surgery was performed when tumors reached approxi-
mately 500 mm3. Mice were anesthetized with intramuscular keta-
mine (80 mg/kg) and xylazine (10 mg/kg) and shaved with hair
clippers before surgery. A 1- to 2-cm incision was made adjacent
to the tumor, and 90% of the tumor was removed using standard
blunt dissection technique. The incision was closed using sterile silk
4-0 sutures. Buprenorphine (0.2 mg/kg) was administered at the time
of surgery and 6 hours after as postoperative analgesia. Preoperative
treatment was unknown to the investigator performing surgery and
making tumor measurements.
In Vivo Depletion of CD8 T Cells
To deplete CD8 T cells during treatment with mch1N11 and cis in
our TC1 model, mice received i.p. injections of 300 μg of monoclonal
antibodies purified from the anti-CD8 hybridoma 53-6.7 (obtained
from the American Type Culture Collection, Manassas, VA). Injections
were administered 1 day before beginning mch1N11 and cis therapies.
Subsequently, mice received biweekly doses throughout the experimen-
tal period to ensure depletion of CD8 T cells. Depletion was confirmed
by flow cytometry of splenocytes.
Immunohistochemical Stains
Animals treated with either C44 control antibody or PS-targeting
antibody were killed when tumor volume curves began to diverge.
Their tumors were harvested and bisected with one half placed either
in Tissue-Tek OCT (Sakura Inc, United Kingdom) and stored at
−80°C or in formalin for paraffin sectioning.
To detect apoptosis, TUNEL staining and cleaved caspase 3 staining
were used. TUNEL staining was performed using ApopTag Plus Peroxi-
dase In Situ Apoptosis Detection Kit (S7101; Chemicon International,
Temecula, CA), following the manufacturer’s instructions. Cleaved cas-
pase 3 stainingwas performed using rabbit anti–cleaved caspase 3 antibody
(no. 9661; Cell Signaling, Danvers, MA). Tissue sections were treated in
heated citrated buffer for antigen unmasking followed by treatment with
3% hydrogen peroxide per the manufacturer’s recommendations.
To detect endothelial cells, monoclonal anti-CD31 (mAB390)
[22] was raised from hybridoma supernatant and purified. Frozen
tumor sections were prepared as previously described [23].
Flow Cytometric Analysis
For flow cytometric analysis, tumors were removed from killed
mice and minced into fine pieces in digestion buffer containing
0.1 mg/ml DNase I and 2.0 mg/ml collagenase type IV (Sigma,
St Louis, MO). Samples were incubated in digestion buffer at 37°C
for 1 hour, filtered through a 70-μm filter, and washed twice with
R10. Fc receptors were blocked with antimouse CD16/CD32 anti-
bodies (BD Biosciences PharMingen, San Diego, CA). After one wash
with PBS plus 2% fetal bovine serum (staining buffer), cells were in-
cubated for 30 minutes at 4°C with appropriate antibodies obtained
from BD Biosciences PharMingen. Samples were then washed and
resuspended in staining buffer or fixed in 2% paraformaldehyde. Flow
cytometry was completed using a Becton Dickinson FACS Calibur
flow cytometer (San Jose, CA) and analyzed using FlowJo software
(TreeStar, Ashland, OR).
Splenocytes and tumor cells were studied by flow cytometric analysis
as previously described [24]. Cells were stained with the following anti-
bodies against the following antigens: Ly6G, Ly6C, CD11b, CD45,
CD8, CD4, F4/80, CD206, 4-1BB, CD137, and GR1. All previously
listed fluorescently labeled antibodies used were purchased from BD
Biosciences, except for CD206-phycoerythrin (PE; obtained from
AbD Serotec, Raleigh, NC), 4-1BB (CD137)–PE (obtained from
Abcam, Boston, MA), and GR1-FITC (obtained from eBioscience,
San Diego, CA).
Statistical Analyses
For flow cytometry, immunohistochemistry, reverse transcription–
polymerase chain reaction, and flank tumor volume studies comparing
differences between two groups, we used unpaired Student’s t tests.
For studies comparing more than two groups, ANOVA with appropri-
ate post hoc testing was implemented. Kaplan-Meier curves were used to
determine the postoperative median survival. Postoperative survival
rates (defined as the time from surgery to the time which flank tumor
volume reached 1500 mm3) for treatment groups were compared using
the log-rank statistic. Differences were considered significant when P <
.05. Data are presented as mean (SE), unless otherwise noted.
Results
Efficacy of PS-Targeting Antibody and Concomitant
Chemotherapy in the TC1 Model
We first evaluated the efficacy of the PS-targeting antibody
mch1N11 alone or in combination with cis chemotherapy in a mouse
model of lung cancer (TC1 tumors). Treatment was started 7 days after
tumor cell inoculation.Mice were treated i.p. with mch1N11, C44, cis,
or the combination of mch1N11 and cis (Figure 1). In this model, cis
slowed tumor growth to some extent, but mch1N11 had little effect
when used alone. Combination therapy was superior to mch1N11 or
cis alone. At day 26, tumor growth was inhibited 87% by combination
therapy and 52% by cis in comparison with the control group (Figure 1,
A and B). The mean tumor volume of the combination group was
216 mm3, and mean the tumor volume of the group receiving C44
alone was 1643 mm3 (P = .02). The group receiving mch1N11 alone
demonstrated little difference from the group receiving C44 antibody
(P > .1). These results show that mch1N11 significantly improves the
therapeutic efficacy of cis for the treatment of the murine NSCLC cell
line TC1 in mice.
Cytotoxic Chemotherapy and Targeted PS Therapy Inhibits
Recurrence of Tumor after Surgery
We next determined whether cis and the PS-targeting antibody
could prevent local recurrences after surgery. Tumors that recur after
surgical resection are known to proliferate rapidly and develop neo-
vasculature. Mice bearing flank TC1 tumor measuring approximately
500 mm3 underwent partial resection of 90% of the tumor [21]. On
postoperative day 3, mice were treated with C44, mch1N11, cis, or
combination therapy. Antibody was given biweekly, and cis was given
weekly. Under these circumstances, mchN11 had a significant anti-
tumor effect in the postoperative tumor microenvironment. At post-
operative day 21, mch1N11 monotherapy reduced the tumor by
44% (Figure 2, A and B; P < .05). As expected, cis alone inhibited
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tumor growth after surgery by 62% (P < .05). The combination of cis
and mchN11 had a strong reduction of recurrent tumors, with mean
tumor volume 90% smaller than control animals (P < .01; Figure 2, A
and B). The mean tumor volume of the combination group at post-
operative day 21 was 206 mm3 in comparison to the control tumor
volume of 1921 mm3 (P = .002). Mice receiving mch1N11 and cis
demonstrated increased postoperative survival in comparison to the
other groups as measured by time to reach a recurrent tumor volume
of 1500 mm3 (P = .03; data not shown). Animals were killed after this
owing to ethical considerations. The surgical wounds of the groups
receiving mch1N11 healed normally and were indistinguishable from
the surgical wounds of the mice receiving C44 or cis.
Mechanisms of Efficacy: Expression of PS on Tumor Cells
Is Minimal
Cis therapy could potentially induce the expression of PS on either
the tumor cells or the associated tumor vasculature. We thus evaluated
whether subtoxic concentrations of cis can induce exposure of PS in
murine NSCLC (TC1) in vitro. TC1 cells were treated with low dose
and high dose of cis for 24 hours at 37°C to determine the expression
of PS. The drug was removed, and cells were stained for annexin V and
7-AAD. Flow cytometry was used to detect PS expression and apop-
tosis. TC1 cells treated with PBS alone demonstrated 4.4% expression
of PS. Treated cells at both concentrations of cis demonstrated less
than 10% apoptosis and similar levels of PS expression (26.3% vs
25.1%), indicating that cis is effective in increasing PS expression at
low and high doses.
Next, we evaluated the externalization of PS in tumor cells in vivo
after injection of cis (5 mg/kg) into immunocompetent mice bearing
established TC1 tumors (250 mm3). The tumors were harvested
24 hours after the cis injection, were digested, and were stained for
annexin V. Flow cytometry demonstrated a marginal increase in PS
exposure in vivo at 24 hours in comparison to control tumor (33% vs
28.5%; Figure 3). Repeat experiments confirmed a small increase
in PS expression in established flank tumors. The PS expression
decreased 48 hours after injection, demonstrating that cis transiently
increased PS expression. Our studies demonstrate that cis induces
only a slight increase in the exposure of PS in NSCLC in mice as
detected by annexin V, making direct binding of the PS-targeting
antibody to tumor cells an unlikely explanation for efficacy.
PS-Targeting Antibody and Cis Induce Apoptosis of Vascular
Endothelial Cells in the Tumor Microenvironment
We next evaluated the tumor vasculature. The ability of combina-
tion mch1N11 and cis to induce apoptosis of tumor cells was analyzed
using a TUNEL assay and cleaved caspase 3 antibody. Mice bearing
TC1 tumor (∼200 mm3) were treated i.p. with C44 (100 μg/mouse),
mch1N11 (100 μg/mouse), cis (6 mg/kg), or combination therapy for
2 weeks. Tumors were harvested 4 days after the last dose of mch1N11
Figure 2. Surgery effectively combines with cis and mch1N11 to
control tumor growth. (A) Mice underwent cytoreduction of tumor
when growth reached approximately 500 mm3. After surgery,
mice received C44, cis, mch1N11, or cis and mch1N11 combined.
(B) Tumor volume at day 39 of mice that underwent surgery and
treatment of TC1 tumor. *P < .01.
Figure 1. TC1 tumor growth is slowed by cis and mch1N11 in vivo.
(A) Mice bearing TC1 tumor were treated with cis and mch1N11
once tumors reached approximately 200 mm3. The group receiv-
ing both treatments demonstrated a dramatic decrease in tumor
growth in comparison to the groups receiving C44 alone, cis alone,
and mch1N11 alone. (B) Tumor volume of tumor bearing mice at
day 26. Mice were treated with C44, cis, mch1N11, or combination
therapy (mch1N11 and cis). *P < .05.
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and analyzed for positively stained apoptotic cells. Tumors from the
combination therapy group demonstrated endothelial cells that posi-
tively stained for apoptosis as demonstrated by the TUNEL assay
(Figure 4A). Furthermore, cleaved caspase 3 staining demonstrated a
significant increase in positively stained cells in the combination ther-
apy group in comparison to all other groups (P = .02; Figure 4B). These
data indicate that cis and mch1N11 are able to induce apoptosis in
tumor endothelial cells.
Mch1N11 Functions in a CD8 T Cell Independent Manner
and Produces an Increase in Intratumoral Neutrophils
To determine whether the antitumor mechanism of mch1N11 is
mediated by the adaptive immune system, we examined the role of
lymphocyte populations on the efficacy of mch1N11. The combina-
tion therapy for mch1N11 and cis on TC1 tumors was repeated in
mice depleted of CD8 T cells. Mice were depleted of CD8 T cells using
a monoclonal rat antimouse antibody. Mice were randomized to five
treatment groups at day 14: C44, mch1N11, combination therapy
(mch1N11 and cis), mch1N11 and CD8 antibody, and combination
therapy plus CD8 antibody. At day 27 after tumor cell inoculation,
mice receiving combination therapy and CD8-depleting antibody
demonstrated no significant difference in tumor size to mice receiving
combination therapy (P > .1; Figure 5A). Furthermore, the two groups
receiving combination therapy demonstrated significant decrease in
tumor volume in comparison to all other groups (P = .02). These data
show that the antitumor efficacy of mch1N11 and cis is independent
of CD8 T cells.
Figure 4. Mch1N11 and cis induce apoptosis in tumor endothelial cells. (A) Mice bearing TC1 tumor were treated with C44, mch1N11,
cis, or a combination of mch1N11 and cis. Tumors were harvested, fixed in formalin, sectioned in paraffin, and stained for apoptosis
using TUNEL staining kit. Only the combination therapy group had apoptotic tumor endothelial cells. (B) Mice bearing TC1 tumor were
treated with C44, mch1N11, cis, or a combination of mch1N11 and cis. Tumors were harvested and frozen in OCT blocks. Tumors were
stained for cleaved caspase 3 antibody. Tumors treated with cis or mch1N11/cis demonstrated significantly increased numbers of
positively stained cells compared with the tumors treated with C44 or mch1N11 alone.
Figure 3. Cis induces little change in PS exposure on TC1 tumor cells.
Mice bearing TC1 tumor (∼200 mm3) were treated with 5 mg/kg
cis, and PS expression on tumors was measured 24 and 48 hours
after treatment.
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Because CD8 T cells did not play a role in the therapeutic efficacy, we
next analyzed recurrent TC1 tumors using flow cytometry and immuno-
histochemistry to further investigate the tumor microenvironment for
other immune cells.Mice bearing large TC1 tumors (∼500mm3) under-
went partial resection of tumor and were treated i.p. with C44,
mch1N11, cis, or combination therapy for 2 weeks. Tumors were re-
sected from all four groups 24 hours after the fourth dose of therapy
and analyzed using flow cytometry and immunohistochemistry. There
was an increase in CD11b cells infiltrating the tumors after combination
therapy (1.6% of entire tumor population) compared with untreated
animals (0.4% of entire tumor; P < .01). We specifically evaluated for
the presence of granulocytes and macrophages.
Intratumoral flow analysis of tumors revealed an infiltration of
neutrophils of those mice which received mch1N11, cis, and combina-
tion therapy (Figure 5B). To confirm this finding, immunohistochem-
istry was performed on frozen sections of tumor. The staining validated
this finding and agrees with previous work that attributes mch1N11’s
efficacy to an increased inflammatory response driven by host cell
infiltration into the perivascular tumor tissues (Figure 5C) [13].
We also evaluated the presence of intratumoral macrophages after
combination cis and mch1N11. There was a significant increase of
leukocytes expressing Ly6C after combination therapy (Table 1). In
addition to the increase of macrophages, the infiltrating macrophages
expressed a predominately M1 phenotype (F4/80hiCD206lo) after
Figure 5. Mch1N11 functions in a CD8 T-cell–independent manner with intratumoral neutrophil infiltration. (A) Mice were randomized into
five groups once tumor size reached approximately 200 mm3: C44, mch1N11, mch1N11/Cis, mch1N11 and anti-CD8 antibody, and
mch1N11/Cis and anti-CD8 antibody. The group receiving mch1N11/cis and anti-CD8 antibody demonstrated no difference in tumor growth
compared with the group receiving mch1N11/Cis alone. This indicates mch1N11 inhibits tumor growth in the absence of CD8 T cells.
(B) Mice bearing recurrent TC1 tumor were treated with C44, mch1N11, cis, or a combination of mch1N11 and cis. Tumors were harvested
and digested for flow cytometry analysis revealing significant neutrophil (Ly6G+) infiltration in mice treated with combination therapy.
(C) Treated tumor sections were stained for Ly6G+ and confirmed the neutrophil infiltration in the perivascular tissues.
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combination therapy. In controls, the ratio of M2 macrophages (F4/
80hiCD206hi) to M1 macrophages suggested a leaning toward a pro-
tumor phenotype (Table 1). However, after combination therapy, there
were twice as many M1 macrophages as M2 macrophages (18.3%
vs 38.3%, respectively). These data suggest that the inflammatory
infiltrate that follows combination therapy is partially responsible for
increased antitumor responses.
Discussion
The objective of this study was to determine whether using targeted
vascular therapy after surgery could inhibit local tumor recurrences
without causing the toxicity associated with other vascular-targeting
agents. Our major finding from this study is that combining mch1N11
with cis slows tumor recurrences after surgery. Our data suggest that the
mechanism is that cis, either directly or indirectly (i.e., by killing tumor
cells that then activates their associated vasculature), increases PS ex-
pression of the tumor vasculature. This vascular PS presents a target
for the mch1N11 antibody that binds and induces intense neutrophil
infiltration, leading to vascular disruption and tumor death. This
process seems independent of the adaptive immune system.
In our studies, we saw some efficacy of the PS-targeting antibody
mch1N11 when used alone in the postsurgical setting (Figure 2A)
but little effect in “unstressed” TC1 tumors (Figure 1A). This is con-
sistent with the idea that the postoperative setting “stimulates/stresses”
the vasculature in the remaining tumor, whereas there is relatively little
baseline expression of PS in unstressed TC1 tumors. One potential
explanation is that tumor relapses occur in tumor microenviron-
ments that are rich in cytokines (VEGF), leukocytes, metabolites,
and reducing/oxidizing factors during their early development. This
rapid proliferation that occurs in a recurrent tumor likely affects the
neovasculature of a developing tumor and may explain the ability of
mch1N11 to inhibit these cancer deposits. This may be a unique fea-
ture of recurrent tumors that can be exploited by PS-targeting therapy.
Importantly, the use of the chemotherapy drug cis markedly enhanced
the efficacy of mch1N11 in both the presurgery and postsurgery setting
and leading to tumor endothelial cell death (Figure 4).
The results here demonstrate that targeting PS on tumor vasculature
can enhance the efficacy of cis and surgery without major toxicity.
The unique postoperative environment provides an ideal time to target
rapidly dividing cells with cis and developing vessels with mch1N11.
Bevacizumab (trade name Avastin) is a drug that blocks angiogenesis
and is currently in clinical use for a wide variety of tumors. However,
this agent has several contraindications surrounding surgery owing
to the increased risk of bleeding and wound healing complications
[4,25]. Although only a small animal model of surgery, we did not have
any of these morbidities with mch1N11. PS-targeting therapy specifi-
cally targets and disrupts tumor vessels as opposed to bevacizumab,
which is an anti-VEGF antibody. This present study contributes to
the previous preclinical and clinical studies showing the promising
nature of PS as a target molecule in recurrent cancers [26].
One of the future studies will be to optimize the pharmacokinetics
of cis with mch1N11. We typically gave mch1N11 24 and 72 hours
after each cis dose. However, this sequence may not be ideal. For
example, we may not require the second dose of antibody for any
benefit. Also, the dose of cis (3 mg/kg) may be reduced owing to
the improved efficacy of the combination, which would lower the
toxicity of this agent. Further investigation is warranted to establish
the pharmacodynamics and pharmacokinetics of cis when vascular
endothelial cells are targeted and damaged after mch1N11 treatment.
The observed decrease in tumor volume in our studies was accom-
panied by an inflammatory infiltrate (CD11b+). Immunostaining
and flow cytometry showed that there was a significant increase in
neutrophils (Ly6G+) into the perivascular tissues (Figure 5, B and
C). Infiltrating neutrophils in tumors have been associated with either
protumor or antitumor immune responses depending on the context
[27]. Our treatment seemed to attract large numbers of antitumor,
N1-type neutrophils. A similar type of response has been noted after
treatment of tumors with photodynamic therapy—another therapy
that may affect tumor vasculature [28]. Macrophages have also been
observed to infiltrate tumors in mice treated with PS-targeting anti-
bodies [12,13,15]. In our study, we postulated that the increased
apoptosis and innate immune response may have stimulated antigenic
cell killing, danger signals, and the induction of antitumor T cells (as
is the case with photodynamic therapy) [28]. However, when we
depleted CD8 T cells, there was no evidence of an adaptive immune
effect. Others have reported that treatment with a PS-targeting anti-
body plus irradiation induced T-cell tumor immunity in a rat glioma
model [14].
One caveat of these data is the experiments that incorporate surgery
depend on a flank tumor model. Flank tumor models have inherent
limitations due to rapid growth kinetics that lack complex host-tumor
interactions and have more acute immune responses [29,30]. In addi-
tion, the orthotopic position does not permit intricate networks that
may develop in a native microenvironment. However, with the excep-
tion of breast and skin cancers, orthotopic tumors (e.g., lung, pancreas,
liver, brain, colon, or the prostate tumors) are not conducive to sur-
gical resection in mice. Our goal was to determine whether PS-targeted
therapy would affect the postoperative tumor milieu; thus, this model
was appropriate and informative.
In conclusion, using a vascular endothelial–targeted therapy after
surgery shows significant promise to prevent lung cancer recurrences
after surgery. This approach is likely due to the unique window of
opportunity after surgery when there is a rapidly proliferating tumor
with significant capillary development and dependence on a source of
oxygen and nutrients. PS-targeting therapy during this time can incite
astrong inflammatory response, partially driven by neutrophils, which
can result in tumor cell killing and improved clinical outcomes.
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